Petersfield, Hampshire, 08 May 2025, Aspire Pharma Limited, a rapidly growing UK-based specialty niche generics business, announces the bolstering of its product portfolio through the purchase of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.
The distribution rights acquisition aligns with Aspire Pharma’s mission to make a difference in the lives of patients through the delivery of an enhanced product portfolio, which Aspire Pharma Chief Executive, Richard Condon, sees further enhancing the business’ growth trajectory.
Mr Condon said:
“We are pleased to announce our latest acquisition, a strategic move that not only strengthens our portfolio but also supports our central mission to meet patient needs, in terms of enhancing supply and access to essential, affordable, medicines.
“By integrating these important products into our existing portfolio, we are reaffirming our commitment to supporting patient care by offering true value to the NHS, payors and healthcare professionals.”
